bharatbook

This report is an essential source for data, analysis and strategic insight into Accuray Incorporated. The report provides key information relating to market share by sector and country, financial, SWOT and value chain analysis of the company. The report examines company’s business structure and operations, history and products, and provides an analysis of its key revenue lines. It inspects the company’s strategy, both in terms of its value chain positioning and strategic strengths and weaknesses.

Scope:-

Revenues for the markets and sub-sectors Accuray Incorporated operates in by country and region.
Detailed breakdowns of revenues and market share benchmarked against competitors.
Profiles of the pipeline of products that the company is developing.
Critical analysis of the company’s strengths, weaknesses opportunities and threats and positioning on the value chain. 
Provides summary analysis of key revenue lines and strategy.
Details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.
Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions.
Latest mergers and acquisitions, partnerships or financings of the company, including debt, equity or venture finance.

 

Reasons to buy:-

 A single source to fulfill all of your business and competitor intelligence needs
 Research your competitors business structure, strategy and prospects.
 Counter your competitors strengths and target their weaknesses.
 Identify your competitors key revenue streams by market and geography.
 Identify and assess potential corporate and investment opportunities
 Support sales activities by understanding your customers businesses better.
 Identify potential competitor products before they reach market.
 Qualify prospective partners and suppliers.

For more information,kindly visit - http://www.bharatbook.com/detail.asp?id=82988

Posted in Health

Posted in Advertising and marketing

Background Info

We are facing a world where microbes once again have the potential to cause untreatable diseases, due to the resistance to virtually all available drugs. WHO suggests that even if the pharmaceutical industry were to step up the efforts to develop new drugs immediately, some diseases might still not have any effective therapies within the next ten years.

How about proving them wrong?

Visiongain is dedicating its Re-emerging infectious diseases conference to the war on drug resistant microbes, uniting researchers from around the world in a unique exchange of thoughts, experiences and ideas. The conference will focus on the future of anti-microbial agents and will provide you with understanding of cutting edge research in:

• DNA-based therapies
• Novel beta-lactam inhibitors
• New drug targets

Key Speakers :-

• David McIntosh, Medical Director, Infectious Diseases, Wyeth
• Alita Miller, Senior Principal Scientist, Pfizer
• Nachum Kaplan, Vice President, Microbiology, Affinium Pharmaceuticals
• Anthony Maxwell, Head of the Department of Biological Chemistry, John Innes Centre
• Michael McArthur, Director of Research, Procarta
• John Overington, Senior Director, Discovery Informatics, Inpharmatica
• Nafsika Georgopapadakou, Vice President, Research, NovaBay Pharmaceuticals
• Lloyd Czaplewski, Director of Research, Prolysis
• Malcolm Page, Head of Biology, Basilea Pharmaceuticals
• Nora Kaarela, Chief Executive Officer, IPSAT Therapies
• Prabhavathi Fernandes, CEO, Cempra Pharmaceuticals
• Steve Barret, Honorary Secretary, Association of Medical Microbiologists
• James Mond, Chief Scientific Officer, Executive Vice President, Biosynexus
• Tom Parr, Chief Scientific Officer, Targanta Therapeutics
• Tanneke den Blaauwen, Assistant Professor, University of Amsterdam

Who will be there?

VPs Directors, Heads, and Managers in:

• Microbiology
• Immunology
• Infectious Diseases
• Medicinal Chemistry
• Clinical Pharmacology
• Drug Discovery
• New Product Development
• Scientific Affairs
• Licensing
• Antibiotics
• Infection Discovery
• Drug evaluation
• Molecular Biotechnology
• Drug development
• Project Management
• Preclinical Development
• Portfolio Management                                                                                                                                                                        

  Day 1

09:30 Registration and refreshments

10:00 Opening address from the chair

Malcolm Page
Head of Biology
Basilea Pharmaceutics

10:10 Novel approaches to prevent hospital infections and antimicrobial resistance

• A major European and global problem
• Preventing infection caused by resistant pathogens
• Emerging mechanisms of antimicrobial resistance

Nora Kaarela
Chief Executive Officer
IPSAT Therapies

10:50 New drug targets for fighting multi-resistant microbes

• General features of good drug targets – do antibacterial targets follow the rules
• Target structural features of resistance
• Development of a general strategy to consider likelihood of resistance in target discovery

John Overington
Senior Director, Discovery Informatics
Inpharmatica

11:30 Morning refreshments

11:50 Discovery and development of novel targeted and broad-spectrum antibacterials

• Anti-staphylococcal cell division inhibitors
• Novel DNA supercoiling inhibitors

Lloyd Czaplewski
Director of Research
Prolysis

12:30 New challenges, new drugs

• Challenging bacterial pathogens
• The magnitude and spectrum of multiresistance
• Antibacterials, in use and in development, to combat multiresistance
• Novel approaches, new drugs

Nafsika Georgopapadakou
Vice President, Research
NovaBay Pharmaceuticals

13:10 Networking lunch

14:30 Developing novel specific spectrum antibiotics for the treatment of staphylococcal infection

• AFN-1252 is a highly potent fatty acid biosynthesis (FabI) inhibitor optimized against staphylococci
• Defined and unique spectrum of activity predicts minimal antibiotic treatment related adverse effects
• Orally efficacious, currently in Phase 1 studies

Nachum Kaplan
Vice President Microbiology
Affinium Pharmaceuticals

15:10 The future of antibiotics

• Are new classes of antibiotics coming?
• Examining how we can use old antibiotics
• What measures can be taken to ensure the effectiveness of future antibiotics
• A brief look at onchocerciasis

David McIntosh
Medical Director Infectious Diseases
Wyeth

15:50 Afternoon refreshments

16:10 Alternate strategies in antibacterial discovery

• Two new lead classes from whole cell screening
• If single targets are not optimum, what are the options?
• Can biological approaches fill the existing/emerging therapeutic gaps?

Alita Miller
Senior Principal Scientist
Pfizer

16:50 Panel Discussion: An efficient strategy for developing novel antibiotics

• How will we find the next generation of antibiotics?
• Should we focus on new drugs or a combination using the ‘classics’?
• Where should our focus be?

David McIntosh, Medical Director Infectious Diseases, Wyeth
Lloyd Czaplewski, Director of Research, Prolysis
Nafsika Georgopapadakou, Vice President, Research, NovaBay Pharmaceuticals
John Overington, Senior Director, Discovery Informatics, Inpharmatica

17:40 Closing remarks from the chair                                                                                                                                

TOP

TOP

TOP

17:45 Networking Drinks Reception
Take your discussions further and build new relationships in a relaxed and informal setting.   

 Day 2

09:30 Registration and refreshments

10:00 Opening address from the chair

Steve Barret
Honorary Secretary
Association of Medical Microbiologists

10:10 DNA-based therapies to combat infectious diseases

• DNA-based therapies to inactivate resistance mechanisms and restore efficacy of antibiotics
• Bacteria can be rendered susceptible to bacteriocidal antibiotics in general
• Procarta has a broad and proprietary technology capable of targeting many bacteria and genetic switches

Michael McArthur
Director of Research
Procarta

10:50 Bacterial DNA gyrase as a target for novel antibacterial agents

• DNA gyrase is a key target for antibacterials: essential in bacteria, lacking in humans
• Many bacterial toxins and antibiotics target gyrase
• High level of understanding of gyrase structure & mechanism
• Significant scope for developing new gyrase-specific antibacterial agents

Anthony Maxwell
Head of Department, Biological Chemistry
John Innes Centre

11:30 Morning refreshments

11:50 An anti-lipoteichoic acid monoclonal antibody to prevent staphylococcal disease in the premature infant

• Completed two phase two trials
• Entering an efficacy trial
• Discussing the implication of the studies

James Mond
Chief Scientific Officer
Executive Vice President
Biosynexus

12:30 Novel β -lactam antibiotics and inhibitor combinations

• Resistance to ß-lactams in Gram-positive and Gram-negative bacteria
• ß-lactams-insensitive penicillin-binding proteins of Gram-positive bacteria
• Emerging ß-lactamases in Gram-negative bacteria
• Anti-MRSA cephalosporins
• ß-lactamase-stable ß-lactams

Malcolm Page
Head of Biology
Basilea Pharmaceutics

13:10 Networking lunch

14:30 Finessing drugs from new & known targets

• Protein synthesis inhibitors have been successful antibiotics
• Useful new antibiotics can be designed by applying new information and technologies to proven classes
• New targets can be identified using old ones
• CEM-101, a product in clinical development, that resulted from this approach will be described

Prabhavathi Fernandes
CEO
Cempra Pharmaceuticals

15:10 – Treatment of Gram-positive infections

• Different approaches to treatment of gram-positive infections
• Discussing the use of old fashion antibiotics
• What should be the next step?

Tom Parr
Chief Scientific Officer
Targanta Therapeutics

15:50 Afternoon refreshments

16:10 – Cell division protein FtsZ as new antibiotic target

• The FtsZ protein is essential for all bacterial cell division
• A wealth of information on FtsZ structure and function is available
• As usual, nature is one step behind

Tanneke den Blaauwen
Assistant Professor
University of Amsterdam

16:50 – Panel Discussion: Comparing different targets for novel antibiotics

• Looking at the efficiency of different drug targets
• Discussing the future of different techniques
• What will the future antibiotics look like, will any of the new drugs dominate?

Anthony Maxwell, Head of Department, Biological Chemistry, John Innes Centre
Alita Miller, Senior Principal Scientist, Pfizer

17:30 Chair’s closing remarks

17:40 End of conference

Partners

Platinum Sponsor:

IMS Health
Operating in more than 100 countries, IMS Health is the world’s leading provider of market intelligence to pharmaceutical and healthcare industries. With $1.8 billion in 2005 revenue and more than 50 years of industry experience, IMS offers leading-edge business intelligence products and services that are integral to clients’ day-today operations, including portfolio optimisation capabilities; launch and brand management solutions; sales force effectiveness innovations; managed care and over-the-counter offerings; and consulting and services solutions that improve ROI and the delivery of quality healthcare worldwide. For further information please visit: www.imshealth.com

Media Partners:

PharmiWeb.com
PharmiWeb.com is the leading industry-sponsored portal for the pharmaceutical sector. Supported by most of the leading pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, features, events listings and international jobs to industry professionals across Europe and the US. For further information please email: corporate@pharmiweb.com

BIOTECHNOLOGY EUROPE
BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY WORLD. It is based and located in Warsaw, Poland. Biotechnology World was founded in 2007 to provide the world’s biotech and pharma information and market to make it universally accessible and useful for scientific and business processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE platform that will allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers companies completed internet public relations, publication and marketing solutions. One of the mains goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to global biotechnology, pharmaceutical and life science activities. For further information please visit www.biotechnology-europe.com

To download conference brochure, please click here..

Fee Per Delegate :

Conference & Workshop	£ 1996.33
Conference Only	£ 1526.33
Workshop Only	£ 703.83

For more information please visit - http://www.bharatbook.com/seminars/Re-emerging_infectious_diseases_2008.asp

Chiral technology, the process of synthesizing or isolating chiral molecules and their single enantiomers, has become big business for a legion of catalyst developers and custom chemical manufacturers. A few of new drugs are single enantiomers, meaning two mirror-image isomers. Enantiomers are the molecules with pair of mirror image isomers. As drugs, single enantiomers often exhibit greater potency and cause fewer side effects than do more conventional drug molecules, which may be chiral but are often equal-parts mixtures of both enantiomers.

Global revenues from chiral technology will soar from $6.63 billion in 2000 to $16.03 billion in 2007, growing at a compound annual rate of 13.4% during that period.

Approximately 80% of all products currently in development for the pharmaceutical industry are based on chiral building blocks, according to Karlheinz Drauz, vice president for technology and R&D management in the fine chemicals business unit of Degussa AG in Hanau-Wolfgang, Germany. Many single-enantiomer chiral drugs have recently hit the market. Among the more successful ones are AstraZeneca's stomach acid remedy Nexium, GlaxoSmithKline's anti-anxiety agent Paxil, and Merck's asthma drug Singulair.

Bharatbook.com included a new report “Understanding Chiral Technologies” which analyzes the technology involved in the chiral processes, cost of the technology, worldwide sales, the different chiral models, major players in the industry, and the basics of the chiral industry. Market overview, market statistics, information for end-users, and much more is included in this report.

 

About Bharatbook.com:

Bharat Book Bureau facilitates companies to take the lead of their industry with best practice business strategies and intelligence, through a unique combination of published reports, databases, country reports, company profiles and customized research services. Bharat Book Bureau provides strategic information tools to the executives, business analysts, and knowledge managers that will help them to probe into and support critical, timely business decisions and strategies.

 

For further information kindly visit: http://www.bharatbook.com/detail.asp?id=79481

 

Posted in Health

INDUSTRY MARKET RESEARCH REPORT   This is the replacement for April 2007 edition of Other Electronic Parts and Equipment Wholesalers in the US report.   Industry Market Research Synopsis   This Industry Market Research report from this provides a detailed analysis of the Other Electronic Parts and Equipment Wholesalers in the US industry, including key growth trends, statistics, forecasts, the competitive environment including market shares and the key issues facing the industry.   Industry Definition   Firms in this industry sell electronic parts and equipment (except electrical apparatus and equipment, wiring supplies and construction material; and electrical appliances, television and radio sets). Products sold in this industry include antennas, blank audiotapes, broadcasting equipment, communications equipment, computer chips and boards, electronic condensers and connectors, integrated circuits, modems, navigational equipment, radio and radar equipment.   Report Contents   The Key Statistics chapter provides the key indicators for the industry for at least the last three years. The statistics included are industry revenue, industry gross product, employment, establishments, exports, imports, domestic demand and total wages.   The Market Characteristics chapter covers the following: Market Size, Linkages, Demand Determinants, Domestic and International Markets, Basis of Competition and Life Cycle. The Market Size section gives the size of the domestic market as well as the size of the export market. The Linkages section lists the industry's major supplier and major customer industries. The Demand Determinants section lists the key factors which are likely to cause demand to rise or fall. The Domestic and International Markets section defines the market for the products and services of the industry. This section provides the size of the domestic market and the proportion accounted for by imports and exports and trends in the levels of imports and exports. The Basis of Competition section outlines the key types of competition between firms within the industry as well as highlighting competition from substitute products in alternative industries. The Life Cycle section provides an analysis of which stage of development the industry is at.   The Segmentation chapter covers the following: Products and Service Segmentation, Major Market Segments, Industry Concentration and Geographic Spread. The Products and Service Segmentation section details the key products and/or services provided by this industry, highlighting the most important where possible to demonstrate which have a more significant influence over industry results as a whole. The Major Market Segments section details the key client industries and/or groups as well as giving an indication as to which of these are the most important to the industry. The Industry Concentration section provides an indicator of how much industry revenue is accounted for by the top four players. The Geographic Spread section provides a guide to the regional share of industry revenue/gross product.   The Industry Conditions chapter covers the following: Barriers to Entry, Taxation, Industry Assistance, Regulation and Deregulation, Cost Structure, Capital and Labor Intensity, Technology and Systems, Industry Volatility and Globalization. The Barriers to Entry section outlines factors that can prevent a new company from entering this industry and also gives an indication of the extent to which this occurs. The Taxation section details all kinds of taxation that are specific or are particularly important to this industry, including taxation concessions. The Industry Assistance section refers to any government and/or other measures designed to improve the performance of this industry. The Regulation and Deregulation section details any applicable regulation and/or deregulation to this industry. The Cost Structure section details the average costs for a company operating in this industry as a percentage of total revenue. The Capital and Labor Intensity section provides a guide to the amount of capital used in production/providing a service compared to the amount of labor in the total mix of inputs. The Technology and Systems section acknowledges the latest technology and/or systems available to this industry within the country. Technology refers to machinery and equipment and systems refers to methods of production that enable better and more efficient production. The Industry Volatility section refers to the year on year fluctuations which occur in industry output. The Globalization section gives an indication of the extent to which the industry is global based on factors such as the level of foreign ownership, the proportion of demand accounted for by foreign operators and the volume of production conducted in other countries.   The Performance chapter provides an analysis of both the industry's Current Performance and Historical Performance. The Current Performance section provides the key analysis for the industry over the past five years with key performance indicators discussed. The Historical Performance section details previously important events in the development of the industry.   The Key Competitors chapter lists the major players in the industry as well as an analysis of each major player's activities in the industry. Market share information is included where possible.   The Key Factors chapter covers the industry's Key Sensitivities and Key Success Factors. The Key Sensitivities section outlines the key factors that are outside the control of an operator in the industry, but are likely to have significant impact on a business. The Key Success Factors section details the factors within the control of an industry operator and which should be followed in order to be successful in the industry. Often this will include behavior that will help to minimize the effects of the Key Sensitivities.   The Outlook chapter is a key analysis section of the report and outlines expectations for the key industry indicators over the next five year period, including forecasts. For more information kindly visit: http://www.bharatbook.com/detail.asp?id=65054

Table of Contents INDUSTRY DEFINITION Activities (Products and Services) Similar Industries Other Related Industries KEY STATISTICS Current Prices Constant Prices Real Growth Ratio Table SEGMENTATION Products and Service Segmentation Major Market Segments Industry Concentration Geographic Spread MARKET CHARACTERISTICS Market Size Linkages Demand Determinants Domestic and International Markets Basis of Competition Life Cycle INDUSTRY CONDITIONS Barriers to Entry Taxation Industry Assistance Regulation and Deregulation Cost Structure Capital and Labor Intensity Technology and Systems Industry Volatility Globalization KEY FACTORS Key Sensitivities Key Success Factors KEY COMPETITORS Major Players Player Performance Other Players INDUSTRY PERFORMANCE Current Performance Historical Performance OUTLOOK Related Reports : Canadian Electronics Industry: Sector Report Chinese Consumer Electronics Industry: An Analysis Chinese Consumer Electronics Industry: Sector Report Chinese Electronics Industry: Sector Report Indian Consumer Electronics Industry: Sector Report Indian Electronics Industry: Sector Report

Posted in Electronic Parts and Equipment